Thursday, August 03, 2017 10:24:58 PM
I firmly agree with bull's strategy of buying in blocks. Never going all in, not until things are just too good to be true. When I am doing good, I strengthen positions in stocks I feel are underperforming. I'm too impatient with my cash, it keeps me from over committing. When stuff like this happens, I start to free up money in those stocks, especially if any of the money I put in previously to other positions is even or up. These prices are a gift. It doesn't matter who our CEO is... there aren't enough shares traded, to keep someone from easily dropping the price of this stock. We are still unknown. There are way too few shares available to allow anyone to keep this stock down though, once we get noticed. It's just the spot we are at. Time will fix it. We didn't need some high powered CEO to steer this ship. We were given great drugs, and a silent partner with significant industry experience. They need drones and wheel greasers, hence the recent hires, and they hired some talented individuals recently. There won't be a big difference between a 1.00 or a 1.40 entry... this will be a big win or a big loss. Two huge trials reporting, both in niche industries, both without current competition that will matter. Market cap is very low, and would still be, even if warrants are exercised.
They want the warrants to be exercised. That's how they work. Every warrant exercised will give the company 1.50. 10 million or so warrants. They will generate 15 million bucks by getting them exercised. It's always the best option for a company. When things are going poorly, we usually see the opposite. Share prices pushed high enough to get warrants exercised. The market is a funny game.
I don't think they will be able to hold the price near these levels or lower for too much longer. Barring crazy news during the earnings call next week, this will begin to bounce within the next 2-3 weeks, as the run up begins. Now that you've seen the game, you can make a lot of money off playing the FDA approval patterns. There are a lot more variations than this one... but this is an easy one to recognize and play. I bought 15K more shares this week. I offer no promise that anything I say will come to pass. It's all a gamble. But this one feels right. I bet on other people's actions, and other people's greed. I doubt anyone is selling shares this low. Who on earth would hold this stock for this long, and sell now, if they were patient enough and didn't sell in march when the delay occurred. There was no additional delay after march, the last patient enrolled occurred precisely around when they indicated it would occur.
Patience friends. Nothing but time will work this out. I've gotten hammered for awhile before, in similar situations when I committed relatively too much, too early. That's the only way I got better. If the trials go well, you'll still do just fine... more than fine. And next time around, when the next stock comes along, you might just make fortunes by doubling down at moments like these. This is the life we chose... can't help but quote The Godfather. There is no reason for them to dilute after the trial. Not that I see. Partnering makes more sense, if the price didn't move enough to get the warrants exercised (which is doubtful).
Good luck guys. Pass the time well. Nobody can stop the clock. Last patient will finish their dosing very soon, one way or another.
Recent VKTX News
- Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 04/24/2024 08:05:00 PM
- U.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures Trading • IH Market News • 04/24/2024 11:31:20 AM
- Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024 • PR Newswire (US) • 04/17/2024 08:05:00 PM
- Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735 • PR Newswire (US) • 03/26/2024 11:03:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 12:54:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 12:52:22 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:52:52 PM
- Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares • PR Newswire (US) • 03/04/2024 09:45:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/01/2024 09:13:40 PM
- Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock • PR Newswire (US) • 02/29/2024 01:50:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/27/2024 10:21:23 PM
- Viking Therapeutics Announces Proposed Public Offering of Common Stock • PR Newswire (US) • 02/27/2024 09:19:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:04:52 PM
- Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity • PR Newswire (US) • 02/27/2024 12:03:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/10/2024 01:59:57 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/09/2024 09:01:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 12:40:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 12:38:45 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/08/2024 09:56:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/08/2024 09:33:26 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/07/2024 10:33:13 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/07/2024 10:24:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 09:09:21 PM
- Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update • PR Newswire (US) • 02/07/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 01:39:53 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM